comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 00:03:11 - browse：78

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： ALS groups 'won't be played again' by the FDA, drug sponsors

hotspot

WSS

Why Marc Tessier

How Brent Saunders' Allergan experiment failed

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Flu vaccine offering decent levels of protection this winter, new data show

What is the Turing Test that determines if computers can think?

Hey, doctors: Don't be no

hotspot

comprehensive

focus

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

How one medical school became remarkably diverse

Pfizer highlights cancer drugs it thinks could reignite investor interest

Affirmative action in medical school literally saved lives

Clinical trials giant ICON acquires HumanFirst

At least 13 dead in Texas as scorching temps continue

FDA does about

United colonoscopy coverage change 'may cost lives,' doctors say

Pfizer highlights cancer drugs it thinks could reignite investor interest

hotspot

RaDonda Vaught to speak at CommonSpirit event on patient safety

The biotech scorecard for the 2nd quarter: 12 industry events to watch

What is the Turing Test that determines if computers can think?

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Kenai launches with $82 million for Parkinson’s stem cell therapy

leisure time

hotspot

leisure time

explore